Reactivation of ER signaling was also evident following the initial administration of lapatinib in some HER2+ breast cancer cell lines, which was followed by reversion to dependence on HER pathways during prolonged exposure to lapatinib43. Here, ERBB2 is linked to breast carcinoma.